CN101744833B - 一种治疗细菌性阴道炎的药物组合物 - Google Patents
一种治疗细菌性阴道炎的药物组合物 Download PDFInfo
- Publication number
- CN101744833B CN101744833B CN2008102378014A CN200810237801A CN101744833B CN 101744833 B CN101744833 B CN 101744833B CN 2008102378014 A CN2008102378014 A CN 2008102378014A CN 200810237801 A CN200810237801 A CN 200810237801A CN 101744833 B CN101744833 B CN 101744833B
- Authority
- CN
- China
- Prior art keywords
- medicine
- release
- pharmaceutical composition
- hypromellose
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000004926 Bacterial Vaginosis Diseases 0.000 title claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 238000003756 stirring Methods 0.000 claims description 32
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 claims description 27
- 229960002291 clindamycin phosphate Drugs 0.000 claims description 27
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 27
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 27
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 27
- 229960003943 hypromellose Drugs 0.000 claims description 27
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 17
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 17
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 16
- 229960000502 poloxamer Drugs 0.000 claims description 16
- 229920001983 poloxamer Polymers 0.000 claims description 16
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 14
- 229920002125 Sokalan® Polymers 0.000 claims description 14
- 229960001631 carbomer Drugs 0.000 claims description 14
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 12
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 12
- 229960003415 propylparaben Drugs 0.000 claims description 12
- 230000008961 swelling Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 abstract description 42
- 229940079593 drug Drugs 0.000 abstract description 27
- 239000000203 mixture Substances 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 10
- 239000000654 additive Substances 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 4
- 210000004877 mucosa Anatomy 0.000 abstract description 3
- 230000007227 biological adhesion Effects 0.000 abstract 3
- 239000003364 biologic glue Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000008187 granular material Substances 0.000 description 20
- 229920001661 Chitosan Polymers 0.000 description 13
- 229940045110 chitosan Drugs 0.000 description 13
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 210000001215 vagina Anatomy 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000001768 carboxy methyl cellulose Substances 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- 206010046914 Vaginal infection Diseases 0.000 description 7
- 229960002227 clindamycin Drugs 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 6
- 229940105329 carboxymethylcellulose Drugs 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229920000148 Polycarbophil calcium Polymers 0.000 description 5
- 239000000227 bioadhesive Substances 0.000 description 5
- 229960001200 clindamycin hydrochloride Drugs 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229960001375 lactose Drugs 0.000 description 5
- 229940057995 liquid paraffin Drugs 0.000 description 5
- 206010025482 malaise Diseases 0.000 description 5
- 229950005134 polycarbophil Drugs 0.000 description 5
- 235000011121 sodium hydroxide Nutrition 0.000 description 5
- 235000010199 sorbic acid Nutrition 0.000 description 5
- 239000004334 sorbic acid Substances 0.000 description 5
- 229940075582 sorbic acid Drugs 0.000 description 5
- 229940099259 vaseline Drugs 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 241001597008 Nomeidae Species 0.000 description 4
- 201000008100 Vaginitis Diseases 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 4
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 4
- 239000000701 coagulant Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- 239000004925 Acrylic resin Substances 0.000 description 3
- 244000144730 Amygdalus persica Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XINCECQTMHSORG-UHFFFAOYSA-N Isoamyl isovalerate Chemical compound CC(C)CCOC(=O)CC(C)C XINCECQTMHSORG-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 235000006040 Prunus persica var persica Nutrition 0.000 description 3
- 239000008156 Ringer's lactate solution Substances 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 229960002900 methylcellulose Drugs 0.000 description 3
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010047786 Vulvovaginal discomfort Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940044977 vaginal tablet Drugs 0.000 description 2
- 239000000003 vaginal tablet Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229940082484 carbomer-934 Drugs 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- WCQDGRGDJWBPJX-UHFFFAOYSA-N propyl 4-hydroxybenzoate;sodium Chemical compound [Na].[Na].CCCOC(=O)C1=CC=C(O)C=C1 WCQDGRGDJWBPJX-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229950004777 sodium calcium edetate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008102378014A CN101744833B (zh) | 2008-12-02 | 2008-12-02 | 一种治疗细菌性阴道炎的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008102378014A CN101744833B (zh) | 2008-12-02 | 2008-12-02 | 一种治疗细菌性阴道炎的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101744833A CN101744833A (zh) | 2010-06-23 |
CN101744833B true CN101744833B (zh) | 2012-05-23 |
Family
ID=42472849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008102378014A Active CN101744833B (zh) | 2008-12-02 | 2008-12-02 | 一种治疗细菌性阴道炎的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101744833B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8765819B2 (en) | 2009-10-08 | 2014-07-01 | Zhongming Zeng | Composition comprising benzoic acid in combination with organic acid preservatives as active ingredients and the use thereof |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101698101B (zh) * | 2008-12-02 | 2011-08-31 | 济南宏瑞创博医药科技开发有限公司 | 一种治疗阴道炎的药物组合物 |
CN102335113A (zh) * | 2010-07-20 | 2012-02-01 | 杭州赛利药物研究所有限公司 | 克林霉素磷酸酯阴道缓释凝胶及其制备方法 |
BRPI1005541A2 (pt) * | 2010-12-27 | 2012-03-20 | Ouro Fino Participações E Empreendimentos S/A | associação farmacêutica fitoterápica, composição farmacêutica fitoterápica, processo de preparação de composição farmacêutica fitoterápica e seus usos veterinários |
CN102283800B (zh) * | 2011-06-29 | 2012-11-21 | 海南海神同洲制药有限公司 | 一种治疗阴道炎的硝酸舍他康唑栓剂及其制备方法 |
CN102274199A (zh) * | 2011-07-26 | 2011-12-14 | 南京生命源医药实业有限公司 | 一种维生素c阴道缓释片 |
CN103405383B (zh) * | 2013-08-14 | 2015-04-22 | 江苏中丹制药有限公司 | 一种克林霉素磷酸酯凝胶剂及其制备方法 |
CN103735491B (zh) * | 2013-12-31 | 2016-01-13 | 哈尔滨欧替药业有限公司 | 克林霉素磷酸酯阴道膨胀栓及其制备方法和检测方法 |
CN106075446A (zh) * | 2016-06-24 | 2016-11-09 | 青岛中腾生物技术有限公司 | 一种缓释妇科凝胶及其制备方法 |
CN105997849B (zh) * | 2016-07-21 | 2019-05-14 | 贵州金玖生物技术有限公司 | 水溶性妇科凝胶及其制备方法 |
CA3039556C (en) * | 2016-10-09 | 2021-06-15 | Shenzhen Eulikan Biotechnology Co., Ltd. | Use of 2-phenylethanol in combination with other antimicrobial agents for vagina |
CN106580981B (zh) * | 2017-01-23 | 2019-04-23 | 牡丹江医学院 | 一种治疗妇科炎症的药物组合物及其制备方法和用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1557330A (zh) * | 2004-01-12 | 2004-12-29 | 杨喜鸿 | 克林霉素缓释制剂 |
CN1559431A (zh) * | 2004-02-18 | 2005-01-05 | 重庆凯林制药有限公司 | 盐酸克林霉素棕榈酸酯分散片及其制备方法 |
CN1748708A (zh) * | 2005-05-31 | 2006-03-22 | 黑龙江龙桂制药有限公司 | 盐酸克林霉素阴道泡腾片及其制备方法 |
CN1823808A (zh) * | 2005-12-14 | 2006-08-30 | 重庆凯林制药有限公司 | 盐酸克林霉素棕榈酸酯分散片及其制备方法 |
CN1872026A (zh) * | 2005-05-30 | 2006-12-06 | 张东军 | 阴道用新型药物制剂 |
CN101292991A (zh) * | 2008-06-20 | 2008-10-29 | 重庆医药工业研究院有限责任公司 | 一种含有克林霉素的复方凝胶剂 |
-
2008
- 2008-12-02 CN CN2008102378014A patent/CN101744833B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1557330A (zh) * | 2004-01-12 | 2004-12-29 | 杨喜鸿 | 克林霉素缓释制剂 |
CN1559431A (zh) * | 2004-02-18 | 2005-01-05 | 重庆凯林制药有限公司 | 盐酸克林霉素棕榈酸酯分散片及其制备方法 |
CN1872026A (zh) * | 2005-05-30 | 2006-12-06 | 张东军 | 阴道用新型药物制剂 |
CN1748708A (zh) * | 2005-05-31 | 2006-03-22 | 黑龙江龙桂制药有限公司 | 盐酸克林霉素阴道泡腾片及其制备方法 |
CN1823808A (zh) * | 2005-12-14 | 2006-08-30 | 重庆凯林制药有限公司 | 盐酸克林霉素棕榈酸酯分散片及其制备方法 |
CN101292991A (zh) * | 2008-06-20 | 2008-10-29 | 重庆医药工业研究院有限责任公司 | 一种含有克林霉素的复方凝胶剂 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8765819B2 (en) | 2009-10-08 | 2014-07-01 | Zhongming Zeng | Composition comprising benzoic acid in combination with organic acid preservatives as active ingredients and the use thereof |
Also Published As
Publication number | Publication date |
---|---|
CN101744833A (zh) | 2010-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101744833B (zh) | 一种治疗细菌性阴道炎的药物组合物 | |
CN101698101B (zh) | 一种治疗阴道炎的药物组合物 | |
CN108635585A (zh) | 一种治疗老年性阴道炎的药物组合物及温敏缓释凝胶剂和制备方法 | |
WO2019205700A1 (zh) | 依达拉奉药物组合物 | |
CN1872026A (zh) | 阴道用新型药物制剂 | |
CN118873509A (zh) | 口服药物组合物 | |
WO2010090371A1 (en) | Aceclofenac-containing controlled-release oral drug preparations and their manufacturing process | |
US20240148693A1 (en) | Composition, preparation method therefor, and use thereof | |
ES2223581T3 (es) | Agonistas beta para el tratamiento de la endometriosis o de la infertilidad o mejora de la fertilidad. | |
CN100387233C (zh) | 左旋吗啉硝唑在制备抗寄生虫感染药物中的用途 | |
CN101574522A (zh) | 一种阴道缓释给药系统 | |
KR101653424B1 (ko) | 성전염성 감염 치료에 사용하기 위한 약학적 조성물 | |
WO2010151004A2 (ko) | 하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물 | |
CN102106882A (zh) | 治疗痤疮及瘢痕的天然药物复方 | |
CN1304002C (zh) | 塞克硝唑阴道泡腾片及其生产方法 | |
CN1709243A (zh) | 含有依布硒啉的阴道内使用药物及其用途 | |
CN102125559B (zh) | 一种含有己酮可可碱和卡络磺钠的药物组合物及其制药用途 | |
CN101703504B (zh) | 一种阴道用药物组合物 | |
CN101744814A (zh) | 一种奥美拉唑复方制剂及其制备方法 | |
CN105362289A (zh) | 一种阴道滞留硼酸制剂及其制备方法 | |
CN111773221A (zh) | 青藤碱及其衍生物或其药物可接受的盐在制备治疗乳腺疾病药物中的应用 | |
CN104887642A (zh) | 一种盐酸林可霉素阴道泡腾片及制备方法 | |
CN115025108B (zh) | 一种用于治疗盆腔炎性疾病的药物组合物及其制备方法 | |
CN108578418A (zh) | 一种治疗糖尿病难愈创面并发症的组合药物 | |
CN103405471A (zh) | 一种含有艾普拉唑钠的复方制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Yang Shuhua Inventor after: Dai Zhijie Inventor after: Wang Dong Inventor after: Gong Honggang Inventor after: Chang Jianhui Inventor after: Deng Shuhai Inventor before: Chang Jianhui Inventor before: Wang Dong Inventor before: Yang Shuhua Inventor before: Gong Honggang Inventor before: Deng Shuhai |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: CHANG JIANHUI WANG DONG YANG SHUHUA GONG HONGGANG DENG SHUHAI TO: YANG SHUHUA CHU ZHIJIE WANG DONG GONG HONGGANG CHANG JIANHUI DENG SHUHAI |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN NANYUE DRUG CO., LTD. Free format text: FORMER OWNER: JINAN PROFOUND PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20131016 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250100 JINAN, SHANDONG PROVINCE TO: 518110 SHENZHEN, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131016 Address after: 518110, 16, Hedong District, Guanlan Road, Guanlan District, Longhua New District, Guangdong, Shenzhen Patentee after: Shenzhen Nanyue Drug Co., Ltd. Address before: 250100, building 3, Pioneer Park, No. 26 Huayang Road, Licheng District, Shandong, Ji'nan Patentee before: Jinan Profound Pharmaceutical Technology Development Co., Ltd. |